4.7 Article

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics

期刊

BLOOD
卷 119, 期 9, 页码 2100-2105

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-11-390658

关键词

-

资金

  1. Mayo Clinic
  2. National Institutes of Health [CA96028, P01 CA62242]
  3. Predolin Foundation
  4. Mayo Clinic Cancer Center
  5. Mayo Foundation
  6. Medtronic
  7. Otsuka
  8. Celgene
  9. Genzyme
  10. BMS
  11. AMGEN
  12. Cylene
  13. Onyx
  14. Millennium
  15. Novartis

向作者/读者索取更多资源

Routine incorporation of FISH into multiple myeloma (MM) diagnostic testing has led to a better appreciation of the heterogeneity of genetic abnormalities associated with this disease. We studied a group of 484 patients with newly diagnosed symptomatic MM to better understand the prevalence of the various abnormalities and the prognostic significance of the overlapping abnormalities. A translocation involving the IgH locus and 1 of the 5 recurrent partner chromosomes was seen in 161 (33%) patients, and 275 (57%) had trisomy of at least 1 odd-numbered chromosome. High-risk FISH, defined as the presence of t(4;14), t(14;16), t(14;20), or loss of P53, was seen in 115 (24%) patients; the median overall survival for this group was 3.9 years, compared with not reached for standard-risk patients (P < .001). Among the patients with high-risk FISH, 49 patients who also had at least 1 trisomy had a median overall survival that was not reached, compared with 3 years for high-risk patients without a concurrent trisomy (P = .01). Based on the current findings, we conclude that the presence of trisomies in patients with t(4;14), t(14;16), t(14;20), or p53 deletion abnormalities in MM ameliorates the usual adverse impact associated with these prognostic markers. (Blood. 2012; 119(9): 2100-2105)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据